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Abstract
Background: Peptidergic neurons containing the melanin-concentrating hormone (MCH) and the
hypocretins (or orexins) are intermingled in the zona incerta, perifornical nucleus and lateral
hypothalamic area. Both types of neurons have been implicated in the integrated regulation of
energy homeostasis and body weight. Hypocretin neurons have also been involved in sleep-wake
regulation and narcolepsy. We therefore sought to determine whether hypocretin and MCH
neurons express Fos in association with enhanced paradoxical sleep (PS or REM sleep) during the
rebound following PS deprivation. Next, we compared the effect of MCH and NaCl
intracerebroventricular (ICV) administrations on sleep stage quantities to further determine
whether MCH neurons play an active role in PS regulation.
Results: Here we show that the MCH but not the hypocretin neurons are strongly active during
PS, evidenced through combined hypocretin, MCH, and Fos immunostainings in three groups of
rats (PS Control, PS Deprived and PS Recovery rats). Further, we show that ICV administration of
MCH induces a dose-dependant increase in PS (up to 200%) and slow wave sleep (up to 70%)
quantities.
Conclusion: These results indicate that MCH is a powerful hypnogenic factor. MCH neurons
might play a key role in the state of PS via their widespread projections in the central nervous
system.
Background
In the middle of the last century, a series of historical
observations lead to the discovery of a sleep phase in
humans and other mammals paradoxically characterized
by cortical activation and rapid eye movements, and asso-
ciated with a complete disappearance of the muscle tone
[1–3]. This phase of sleep, coined paradoxical sleep (PS)
or rapid eye movement (REM) sleep was then demon-
strated to correlate with dream activity [3,4]. It was soon
reported by Jouvet [5] that the state of PS is still present in
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"pontine cats" in which all structures rostral to the brain-
stem have been removed. This seminal experiment dem-
onstrated that the brainstem contains the structures
responsible for the generation of PS. Following this clear-
cut demonstration, the potential role of the forebrain has
therefore been poorly studied. However, a few studies sug-
gest that the posterior hypothalamus might play a role in
PS homeostasis. It has been shown that reversible inacti-
vation of the lateral hypothalamic area by muscimol (a
GABAa agonist) applications induces a disappearance of
PS [6]. In addition, neurons specifically active during PS
have been recorded in the same area [7,8]. Finally, it has
recently been shown that narcolepsy, a sleep disorder
characterized by excessive daytime sleepiness and cata-
plexy, is due to the lack of hypocretin mRNA and peptides
in Humans [9] or a disruption of the hypocretin receptor
2 or its ligand in dogs and mice [10,11]. Interestingly,
hypocretin neurons are localized exclusively in the dorso-
medial, lateral and perifornical hypothalamic areas [12].
Neurons containing another peptide, melanin-concen-
trating hormone (MCH), co-distributed with hypocretin
neurons could also play a role in PS control. Indeed, like
the hypocretin neurons, they send strong projections to
brainstem structures responsible for the onset and main-
tenance of PS [12–14]. Moreover, abundant putative con-
tacts between both types of neurons have been observed,
suggesting that both populations may interact at the
hypothalamic level [15]. To determine whether the neu-
rons from the lateral hypothalamic area and the periforni-
cal nucleus and more specifically those containing
hypocretin and MCH are indeed implicated in PS home-
ostasis, we combined Fos, hypocretin and MCH immuno-
histochemistry in rats deprived of PS, with enhanced PS
during rebound after PS deprivation and in control condi-
tion. We chose this method because the examination of
Fos, the product of the immediate early gene cfos that is
expressed in association with neuronal discharge and
entry of Na+ and Ca2+ ions, is now well-accepted to study
neuronal activity [16,17]. In addition, it has been recently
and successfully used to localize and characterize the
chemical identity of the brainstem neurons responsible
for PS generation [18–20].
Using this method, we found that the large majority of
MCH, but not hypocretin neurons are immunoreactive to
Fos specifically after PS hypersomnia. To further deter-
mine whether MCH play a direct role in PS regulation, we
designed a second series of experiments in which we com-
pared the effect on the sleep-waking cycle of ICV injection
of different doses of MCH with that of NaCl injections.
Results
Sleep recording data
The PS deprivation procedure was effective in producing a
near complete elimination of PS in the group of rats per-
fused after the 72 h of deprivation (PSD group) and also
in that subjected to the same deprivation and then
allowed to recover for three hours before perfusion (PSR
group). These two groups of rats presented no significant
difference in their quantities of PS (PSD: 4.4 ± 2.5 min,
PSR, 4.8 ± 3.0 min), SWS (PSD: 1348.5 ± 80.0 min, PSR,
1375.6 ± 136.6 min) and W (PSD: 2965.9 ± 83.2 min,
PSR, 2929.3 ± 129.2 min) during the 72 h of deprivation.
During the 150 min prior to sacrifice, the quantities of PS
were significantly different in the PSD and PSR groups and
in the group of control animals (PSC group) (p < 0.05).
The state of PS constituted 16 % of the last 150 minutes
prior to sacrifice in the PSC group, 0 % in the PSD group
and 44 % in the PSR group (Table 1). There was a signifi-
cant decrease in the time spent in slow wave sleep (SWS)
in PSD (30 %) and PSR (33 %) conditions as compared to
the PSC (48 %) condition (p < 0.05). The PSD group pre-
sented a large quantity of waking (W) (70%) compared to
the PSC (36%) and PSR (23%) groups. The increase in PS
quantities during the last 150 minutes prior to sacrifice in
the PSR group compared to the PSC group was due to a
significant increase in the duration of the PS bouts (PSC,
1.2 ± 0.1 min; PSR, 2.5 ± 0.2 min) (p < 0.001). The
number of bouts did not vary significantly between the
two groups (PSC, 21.2 ± 2.3; PSR, 27.2 ± 3.9).
Fos expression in the posterior hypothalamus across 
vigilance states
The number of Fos+ neurons located in the posterior
hypothalamus as a whole was highly significantly
increased in the PSR group compared to the PSC and PSD
groups (Figs. 1 and 2) (Table 1). The mean number of
Fos+ neurons was superior in the PSD group compared to
the PSC group but it did not reach statistical significance
(Table 1). Across conditions, the number of Fos+ neurons
in the posterior hypothalamus was positively correlated
with the percent PS (R = 0.648, p < 0.05) and showed no
correlation with the percent wake (R = 0.337) or the per-
cent SWS (R = 0.418).
The largest number of Fos+ neurons in the PSR group was
localized in the lateral hypothalamic area (151.6 ± 12.2
neurons per hemi-section). A substantial number of
labeled cells was also observed in the rostral part of the
zona incerta (77.0 ± 17.6 neurons per hemi-section), per-
ifornical nucleus (55.7 ± 4.9 neurons per hemi-section),
dorsal hypothalamic area (56.2 ± 9.7 neurons per hemi-
section) and ventromedial hypothalamic nucleus (50.0 ±
15.7 neurons per hemi-section). A small number of cells
was localized in the dorsomedial hypothalamic nucleus
(36.7 ± 6.8 neurons per hemi-section) and the caudal part
of the zona incerta (22.5 ± 3.6 neurons per hemi-section).
In all these structures, excepting the lateral and dorsal
hypothalamic areas, the number of Fos+ cells in the PSCBMC Neuroscience 2003, 4 http://www.biomedcentral.com/1471-2202/4/19
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Photomicrographs of double-immunostained sections from a rat belonging to the PS-Recovery condition Figure 1
Photomicrographs of double-immunostained sections from a rat belonging to the PS-Recovery condition. A, 
Three double-labeled MCH+/Fos+ cells with their cytoplasm colored in brown and their nucleus labeled in black and one single 
labeled MCH+ cell. B, Fos+ (with a black nucleus) and hypocretin (with a brown cytoplasm) single labeled cells. Scale bars: 20 
µm.
Table 1: Sleep stages quantities and cell counts for control (PSC), PS deprived (PSD) and PS recovery (PSR) groups.
PSC PSD PSR
W 53.48 ± 3.65 104.55 ± 10.14¶¶¶ 34.48 ± 4.80###
SWS 72.08 ± 3.93 45.63 ± 10.16¶ 49.40 ± 4.95 *
PS 24.6 ± 0.4 0.0 ± 0.0¶¶¶ 65.8 ± 4.0 ***, ###
Fos+ 25.00 ± 11.16 160.42 ± 32.13 445.24 ± 70.11 *** , ##
Hypocretin+ 92.25 ± 7.40 113.07 ± 9.06 96.34 ± 3.25
Hypocretin+/Fos+ 0.06 ± 0.06 3.31 ± 0.90¶ 2.03 ± 0.86
MCH+ 201.17 ± 12.18 186.50 ± 12.15 195.00 ± 8.75
MCH+/Fos+ 0.13 ± 0.13 0.27 ± 0.11 113.46 ± 4.72 ***, ###
Time spent in W, SWS and PS is reported in minutes, scored per 10 sec epochs over the last 150 minutes of the experiment. The number (mean ± 
SEM) of Fos+, MCH+, Hypocretin+ and double-labeled neurons (Hypocretin+/Fos+ or MCH+/Fos+) was calculated in the posterior hypothalamus 
for control (PSC, n = 4), PS deprived (PSD, n = 4) and PS recovery (PSC, n = 4) rats. Cells were counted on 4 and 6 hemi-sections per animal for 
Hypocretin/Fos and MCH/Fos labelings respectively. Significance values indicated for individual points are: ¶ p < 0.05 and ¶¶¶ p < 0.001 between PSD 
and PSC, * p < 0.05 and *** p < 0.001 between PSR and PSC, ## p < 0.01 and ### p < 0.001 betweenPSR and PSD conditions.BMC Neuroscience 2003, 4 http://www.biomedcentral.com/1471-2202/4/19
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and PSD group was very limited and not statistically dif-
ferent between the two groups and significantly inferior to
the PSR group. In the lateral and dorsal hypothalamic
areas, the number of Fos+ neurons was significantly supe-
rior in the PSD group compared to the PSC group (p <
0.05) and significantly inferior compared to the PSR
group (P < 0.05).
In all groups, the arcuate nucleus of the hypothalamus
contained only a few Fos+ cells.
Fos expression in hypocretin and MCH neurons across 
vigilance states
In all groups, only a few to occasional hypocretin neurons
expressed Fos (PSR, 2%; PSD, 3%; PSC, 0.1% of all the
hypocretin neurons counted) (Fig. 1A) (Table 1). The
number of Hypocretin+/Fos+ cells was neither correlated
with the percent waking (R = 0.396), the percent SWS (R
= -0.455) nor the percent PS (R = -0.19).
In contrast to hypocretin, the majority of the MCH+ cells
were immunoreactive to Fos in the recovery condition
(Fig. 1B, Fig. 2C) whereas only a few were Fos+ in the dep-
rivation and control conditions (PSR, 58%; PSD, 0.2%;
PSC, 0.1% of all the MCH neurons counted) (Fig. 2)
(Table 1). Across conditions, the number of MCH+/Fos+
cells was significantly and positively correlated with the
percent time spent in PS (R = 0.917, p < 0.0001) and neg-
atively correlated with the percent waking (R = -0.65, p <
0.05). It was not significantly correlated with the percent
SWS (R = -0.28). In the PSR condition, the MCH+/Fos+
neurons made up for 76 % of the Fos+ neurons localized
Schematic distribution of Fos+ (grey dots), MCH+ (black dots) and MCH+/Fos+ (red dots) neurons on two coronal hemi-sec- tions of the hypothalamus in a representative animal for PS-Control (A1, A2), PS-Deprivation (B1, B2) and PS-Recovery (C1,  C2) conditions Figure 2
Schematic distribution of Fos+ (grey dots), MCH+ (black dots) and MCH+/Fos+ (red dots) neurons on two 
coronal hemi-sections of the hypothalamus in a representative animal for PS-Control (A1, A2), PS-Depriva-
tion (B1, B2) and PS-Recovery (C1, C2) conditions. Note the very large number of MCH+/Fos+ cells specifically in the 
PSR condition. Abbreviations: Arc, arcuate nucleus; DA, dorsal hypothalamic area; DMH, dorso-medial hypothalamic area; f, 
fornix; ic, internal capsule; LHA, lateral hypothalamic area; mt, mammillothalamic tract; opt, optic tract; PeF, perifornical area; 
VMH, ventro-medial hypothalamic area; ZI, zona incerta.BMC Neuroscience 2003, 4 http://www.biomedcentral.com/1471-2202/4/19
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in the perifornical area, 60% of the Fos+ neurons in the
lateral hypothalamic area and 34% of the Fos+ neurons in
the rostral zona incerta.
Effect of MCH ICV administrations on the sleep-wake 
cycle
The injection of 0.02, 0.2, 1 and 5 µg of MCH into the left
lateral ventricle of rats at dark onset induced a dose-
dependant and significant increase in the amount of PS
(Fig. 3, Table 2). Injection of 10 µg of MCH had no signif-
icant effect. The strongest increases in PS quantities were
obtained with 0.2 and 1 µg MCH doses. The maximum
increase with these two doses compared to NaCl was seen
during the first two hours (0.2 µg, 198%; 1 µg, 174%) (p
< 0.01). The increase of PS quantities following 0.2 and 1
µg injections was visible during 8 and 4 h, respectively
(Fig. 3, Table 2). The injection of 0.02 µg of MCH induced
a smaller increase in PS quantity compared to NaCl with
a maximum increase again during the first two hours
(137%) (p < 0.05). With this dose, PS quantities remained
significantly increased only during the first four hours
compared to saline. The 5 µg MCH dose significantly
increased PS quantities compared to NaCl but only during
the third and fourth hours (119%)(p < 0.01).
For the 0.2, 1 and 5 µg doses, the increase in PS quantities
was due to an increase in the number of bouts of PS and
not in their duration (Fig. 4). In the case of the 0.02 µg
injections, the number of bouts and their duration were
not significantly modified. For all doses, the latency of the
first PS episode was unchanged compared to NaCl.
In addition to the effect on PS, a significant increase in
SWS and a decrease in W quantities were obtained after
administration of 0.2 and 1 µg of MCH compared to NaCl
(p < 0.05) (Fig. 3, Table 2). Injection of 10 µg of MCH also
induced an increase in SWS and a decrease in W quantities
compared to NaCl, which did not reach statistical signifi-
cance. No effect on SWS and W was seen with 0.02 and 5
µg doses compared to NaCl. The increase in SWS quanti-
ties following 0.2 and 1 µg MCH injections was maximal
during the first two hours (0.2 µg, 69%; 1 µg, 73%) (p <
0.05) (Fig. 3, Table 2). The maximum decrease in W
amounts was seen during the first 2 hours for 0.2 µg (-
25%) and the third and fourth hours for 1 µg (-35%). The
0.2 and 1 µg MCH injections significantly increased SWS
and decrease W quantities during 2 and 6 h compared to
NaCl, respectively (Fig. 3, Table 2).
Discussion
In the present study, we found that a large majority of the
MCH but not the hypocretin neurons were strongly
immunoreactive to Fos specifically after a PS hypersomnia
following 72 h of PS deprivation. Both types of cells were
not immunoreactive to Fos in control condition or after
the 72 h PS deprivation. Further, we found that ICV
administration of 0.02, 0.2, 1 and 5 µg of MCH induces a
dose dependent increase in PS and, to a minor extent,
SWS quantities.
Our study is the first reporting the presence of Fos-immu-
noreactive neurons in the posterior hypothalamus after PS
rebound. Indeed, previous studies examining Fos expres-
sion after PS hypersomnia focused on the brainstem [18–
20]. Our results suggest that MCH neurons and also other
populations of neurons intermingled with them and in
adjacent structures, like the dorsal hypothalamic area, are
specifically active during PS. They are supported by elec-
trophysiological studies showing the presence of neurons
strongly active during PS in the posterior hypothalamus
[7,8]. Our results also indicate that hypocretin neurons
are inactive during PS. They are in agreement with previ-
ous studies showing that Fos expression in hypocretin
neurons is correlated positively with the amount of W and
negatively with the amounts of SWS and PS during the 2
h prior to sacrifice [21]. Altogether, these and our results
indicate that hypocretin are active during W and inactive
during SWS and PS, while MCH neurons are active during
PS.
The next step is to determine the role(s) of the MCH neu-
rons during PS. It is unlikely that they are responsible for
PS onset and maintenance since it is well accepted that PS
generating structures are restricted to the brainstem [22].
However, MCH neurons could play a role in PS homeos-
tasis. Indeed, reversible inactivation, by muscimol (a
GABAa agonist) applications, of the region containing the
MCH neurons induces a disappearance of PS [6]. Further,
MCH fibers and receptors are present in the brainstem, in
particular in reticular structures known to trigger PS like
the sublaterodorsal, dorsal raphe nucleus and locus coer-
uleus nuclei [13].
To test the hypothesis that MCH neurons play a role in the
homeostasis of PS, we studied the effect of ICV adminis-
trations at dark onset of MCH. Dark onset was chosen
because the quantities of SWS and PS are minimal at this
circadian time and an increase in their quantities was
therefore more likely to be unraveled. We found that such
injections induce a dose-dependant increase in PS and, to
a minor extent, SWS quantities. These pharmacological
results suggest that MCH neurons directly regulate PS and
SWS quantities.
The mechanism of action remains to be determined. One
possibility is that MCH increases PS via a direct excitation
of the brainstem PS inducing neurons (PS-on neurons), in
particular those located in the sublaterodorsal nucleus
[23]. This seems however quite unlikely because MCH has
been shown to be an inhibitory peptide [24,25] andBMC Neuroscience 2003, 4 http://www.biomedcentral.com/1471-2202/4/19
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Increase of paradoxical sleep and slow wave sleep quantities by ICV administration of MCH Figure 3
Increase of paradoxical sleep and slow wave sleep quantities by ICV administration of MCH. Administration of 0.2 
µg (black line) and 1 µg (dashed line) of MCH induceda strong increase in the quantities of PS (A) and SWS (B) and a decrease 
in W (C) in male rats compared to NaCl (dotted line). The values are normalized to NaCl, NaCl corresponding to 100% of PS 
(A), SWS (B) or W (C). Significance values indicated for individual points are: 0.2 µg MCH versus NaCl ( * p < 0.05, **p < 0.01), 
1 µg MCH versus NaCl (° p < 0.05, ° °p < 0.01).
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GABA has been shown to be co-localized with MCH [26].
It is therefore more likely that MCH neurons promote PS
indirectly by inhibiting neurons themselves inhibiting the
PS executive neurons during W and SWS (PS-off neurons).
The monoaminergic neurons in the brainstem and the
histaminergic neurons in the caudal hypothalamus
belong to this category. They are active during W, decrease
or nearly cease their activity during SWS and are silent
during PS [7,27,28]. In previous studies, we have shown
that GABA tonically inhibits the pontine PS executive neu-
rons localized in the sublaterodorsal nucleus [23]. Fur-
ther, we localized in the ponto-mesencephalic reticular
formation the GABAergic neurons potentially responsible
for this inhibition [29]. The increase of PS induced by
MCH could therefore also be due to a direct inhibition of
these GABAergic neurons.
Another possibility is that MCH neurons modulate SWS
and PS quantities via an inhibitory action on the inter-
mingled hypocretin neurons. Indeed, our and other [21]
results indicate that hypocretin neurons are active during
W and inactive during PS. In addition, disappearance of
the hypocretins or invalidation of the receptor 2 for these
peptides have been shown to induce narcolepsy in
Human [9], mice [11] and dogs [10], the main feature of
this disorder being sleepiness and PS attacks during W.
Further, putative somasomatic, axosomatic and axoden-
dritic contacts between hypocretin and MCH neurons
have been observed, suggesting that MCH and hypocretin
neurons are interconnected [15]. From these and our
results, it can be hypothesize that MCH neurons might
provide a tonic inhibition of the hypocretin neurons and
by this way promote sleep.
Neurons containing MCH also project to forebrain struc-
tures such as the hippocampus and cortex [13,30,31].
Therefore, in addition to its role in PS homeostasis, the
release of MCH on the cortical and hippocampal cells,
specifically during PS, could also be involved in the induc-
tion of gamma and theta activities and oscillations
observed on the EEG during PS. Additional studies are
now necessary to determine the role of MCH release dur-
ing PS in these brain territories.
Besides, it has been previously shown that central admin-
istration of 1.5 or 5 µg of MCH stimulates food intake
while 0.15 and 0.5 µg doses are ineffective [32]. We found
that lower doses (0.2 and 1 µg) more efficiently increase
the quantities of PS, suggesting the existence of different
modes of action of MCH on sleep and food intake. Addi-
tional studies are now necessary to unravel the link
between the presumed role of MCH in sleep and nutri-
tional homeostasis.
Conclusions
In conclusion, our results indicate that MCH is a powerful
peptidergic hypnogenic factor. They further suggest that
MCH-containing neurons play a crucial role in PS home-
ostasis in addition to energy balance [32–36]. Since MCH
increases the quantities of PS but also those of SWS, it will
be of interest to determine whether MCH agonists could
be useful to treat sleep disorders such as insomnia.
Methods
Animals and surgery
All animals were housed and cared for according to the
National Institute of Health "Guide for the care and use of
Increase in the number of PS bouts after ICV administration of MCH Figure 4
Increase in the number of PS bouts after ICV administration of MCH. Histograms illustrating the number of PS bouts 
(A) and their duration (B) during the first four hours following ICV administration of NaCl, 0.02, 0.2,1, 5 or 10 µg of MCH 
(mean ± SEM). There is a significant difference in the number of PS bouts between NaCl and MCH injections for 0.2, 1 and 5 
µg. No difference in PS bouts duration was observed. Significance values indicated are for MCH versus NaCl injections ( *p < 
0.05, **p < 0.01, ***p < 0.001).BMC Neuroscience 2003, 4 http://www.biomedcentral.com/1471-2202/4/19
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laboratory animals" (NIH publication 80–23). Male
Sprague-Dawley rats (280–320 g, n = 25; IFFA Credo)
were prepared for electroencephalogram (EEG) and elec-
tromyogram (EMG) monitoring under chloral hydrate
anaesthesia (400 mg/kg, i.p.) as previously described [23].
They were placed under a 12 h/12 h light/dark cycle
(lights on from 6:00 AM to 6:00 PM) and constant tem-
perature (23°C) in a Plexiglas jar for at least 8 days of
habituation.
Polygraphic recordings
EEG and EMG recordings were collected on a computer
via a CED interface using the Spike 2 software (Cambridge
Electronic Design). Vigilance states were discriminated
with the aid of EEG and EMG data as previously described
[23].
Paradoxical sleep deprivation procedure
PS deprivation was performed during 72 h using the clas-
sical flowerpot method [18,19,37]. Food and water were
accessible ad libitum to animals. A 24 h baseline recording
was first performed for all animals. Then, the rats were
divided in control (PSC, n = 4), PS deprivation (PSD, n =
4) and PS rebound (PSR, n = 4) groups. The animals of the
PSC group remained in their recording jar for 5 days
before anaesthesia and perfusion at 5:00 PM. The animals
of the PSD group were placed on platforms (6.5 cm in
diameter) over water at 1:00 PM for three days and then
anesthetized and perfused at ≅ 4:30 PM. The animals of
the PSR group were placed on platforms for 72 h of PS
deprivation and then back in their home cage for ≅ 3 h to
allow a recovery of PS. They were anaesthetized for per-
fusion 150 min exactly after the first PS episode.
Neuroanatomical experiments
The PSC, PSD and PSR animals were perfused with a
Ringer's lactate solution containing 0.1% heparin, fol-
lowed by 500 ml of a fixative composed of 4% parafor-
maldehyde and 0.2% picric acid in 0.1 M phosphate
buffer (PB, pH 7.4). Brains were postfixed for 2 h at 4°C
and then stored for 2 days at 4°C in PB with 30% sucrose.
The brains were rapidly frozen with CO2 gas, sliced in 25
µm-thick coronal sections, and stored in PB containing
0.9% NaCl, 0.3% Triton X-100 and 0.1% sodium azide
(PBST-Az). They were successively incubated in (i) a rab-
bit antiserum to Fos (1:5,000; Oncogene) in PBST-Az for
3 days at 4°C; (ii) a biotinylated goat antirabbit IgG solu-
tion (1:2,000; Vector Laboratories); and (iii) an ABC-HRP
solution (1:1,000; Elite kit, Vector Laboratories) both for
90 min at room temperature. Finally, the sections were
immersed in a 0.05 M Tris-HCl buffer (pH 7.6) containing
0.025% 3,3'-diaminobenzidine-4 HCl (DAB; Sigma),
0.003% H2O2 and 0.6% nickel ammonium sulphate. Two
washes of 30 min were performed between each step.
The Fos stained sections were incubated the following day
in a rabbit antiserum to either hypocretin (1:10,000;
Phoenix Pharmaceutical) or MCH (1:100,000; Phoenix
Pharmaceutical) in PBST-Az over 3 days at 4°C. Amplifi-
cation steps were similar to those above but revelation
was performed in DAB solution without nickel. Finally,
the sections were mounted on slides, dried and cover-
slipped with DePex.
Cell counts and analysis of immunohistochemical data
Drawings of double-immunostained hemi-sections were
made with a Leitz Orthoplan microscope equipped with
an X/Y sensitive stage and a video camera connected to a
computerized image analysis system (Historag, BIO-
COM). Single and double-labeled neurons were counted
in each hypothalamic structure present on one side of 6
MCH/Fos double-labeled sections and 4 hypocretin/Fos
double-labeled sections.
ICV injections
For all rats, a guide cannula was implanted into the left
lateral ventricle. Animals were allowed to recover for 3
days and were handled daily during 5 days prior to injec-
tion to minimize non-specific stress. Five microliters of
MCH (0.02 µg, n = 4; 0.2 µg, n = 7; 1 µg, n = 7, 5 µg, n =
9 and 10 µg, n = 5 dissolved in 0.9% saline) or saline (n =
13) were administered at the rate of 1 µl/min at the begin-
ning of the dark period (6:00 PM), with a stainless steel
injector placed in the cannula and connected to an Ham-
ilton syringe (Hamilton, Bonaduz, AG) by polythene tub-
ing (id, 0.5 mm; od, 1 mm). All animals received at least
one saline injection and one dose of MCH. After injection,
animals returned to their jars and vigilance states were
recorded for 8 h. The placement of the cannula was veri-
fied at the end of the study by microscopic examination of
coronal counterstained brain sections.
Statistical analysis
ANOVA were performed on the different vigilance states
across experimental conditions. A post hoc PLSD Fisher test
was used to identify significant pairwise differences. The
same tests were performed to compare cell counts
between the animals groups in the different hypothalamic
structures. Cell counts were correlated with physiological
variables using a simple linear regression analysis. All sta-
tistics were performed using Statview 5.0.
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